Saltar al contenido
Merck

The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening.

Bioorganic & medicinal chemistry letters (2011-05-04)
Peter Vella, Waleed M Hussein, Eleanor W W Leung, Daniel Clayton, David L Ollis, Nataša Mitić, Gerhard Schenk, Ross P McGeary
RESUMEN

The emergence of metallo-β-lactamases (MBLs) capable of hydrolysing a broad spectrum of β-lactam antibiotics is particularly concerning for the future treatment of bacterial infections. This work describes the discovery of lead compounds for the development of new inhibitors using a competitive colorimetric assay based on the chromogenic cephalosporin CENTA, and a 500 compound Maybridge™ library suitable for fragment-based screening. The interactions between identified inhibitory fragments and the active site of the MBL from Klebsiella pneumoniae and Pseudomonas aeruginosa were probed by in silico docking studies.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Captopril, ≥98% (HPLC), powder
Sigma-Aldrich
Captopril, meets USP testing specifications